12.02.13
EOS Imaging, a developer of two- and three-dimensional orthopedic medical imaging, is expanding into Japan.
The company recently announced that Niigata Spine Center is the first center in Japan to install the EOS system. The company obtained regulatory approval in Japan last month, which the company characterizes as the world’s second-largest medical imaging market.
Niigata Spine Surgery Center is specialized in all spinal conditions and treatments for adult and children and has a strong clinical research activity, with more than 150 scientific papers presented in the last five years at Japanese or international meetings.
“I am very happy that our hospital is the first in Japan to be equipped with EOS,” Professor Hasegawa, head of the center, said. “I have followed the progress of this technology and its remarkable adoption worldwide, from which I received excellent feedback. I am confident that EOS will quickly be successful in Japan and look forward to use it now for my patients.”
Marie Meynadier, CEO of EOS imaging, said: “We are pleased that the unique benefits of the EOS system will now be available to patients in Japan, the second largest medical imaging market after the United States. The installation at Niigata Spine Center approximately one month following regulatory approval demonstrates the strong interest in the EOS system in Japan and the positive results from our market development efforts with our local distribution partner. We look forward to continue expanding adoption of the EOS system in Japan, which is a key component of our strategy in the Asia-Pacific region.”
EOS Imaging’s medical imaging system is based on technology that enabled George Charpak to win the Nobel Prize for Physics. The company has sales in 31 countries, including the United States, Japan, Canada, Australia and the European Union. The company posted 2012 revenue of approximately $12.4 million and employs 70 people including an R&D team of 25 engineers. EOS is based in Paris, France, and has officers or facilities in Cambridge, Mass.; Montreal, Canada; Griesheim, Germany and Singapore.
The company recently announced that Niigata Spine Center is the first center in Japan to install the EOS system. The company obtained regulatory approval in Japan last month, which the company characterizes as the world’s second-largest medical imaging market.
Niigata Spine Surgery Center is specialized in all spinal conditions and treatments for adult and children and has a strong clinical research activity, with more than 150 scientific papers presented in the last five years at Japanese or international meetings.
“I am very happy that our hospital is the first in Japan to be equipped with EOS,” Professor Hasegawa, head of the center, said. “I have followed the progress of this technology and its remarkable adoption worldwide, from which I received excellent feedback. I am confident that EOS will quickly be successful in Japan and look forward to use it now for my patients.”
Marie Meynadier, CEO of EOS imaging, said: “We are pleased that the unique benefits of the EOS system will now be available to patients in Japan, the second largest medical imaging market after the United States. The installation at Niigata Spine Center approximately one month following regulatory approval demonstrates the strong interest in the EOS system in Japan and the positive results from our market development efforts with our local distribution partner. We look forward to continue expanding adoption of the EOS system in Japan, which is a key component of our strategy in the Asia-Pacific region.”
EOS Imaging’s medical imaging system is based on technology that enabled George Charpak to win the Nobel Prize for Physics. The company has sales in 31 countries, including the United States, Japan, Canada, Australia and the European Union. The company posted 2012 revenue of approximately $12.4 million and employs 70 people including an R&D team of 25 engineers. EOS is based in Paris, France, and has officers or facilities in Cambridge, Mass.; Montreal, Canada; Griesheim, Germany and Singapore.